- Janssen files for HIV combination therapy in Europe
Janssen-Cilag has submitted a marketing application to the European Medicines Agency for a new once-daily darunavir-based single tablet regimen (STR) to treat HIV.
- NICE extends use of Eylea (aflibercept, Bayer)
Cost regulators are now extending National Health Service (NHS) use of Eylea (aflibercept, Bayer) for all patients with visual impairment due to branch retinal vein occlusion (BRVO), having initially confirmed its use only in the second-line setting.
- NICE broadens NHS treatment options for CML, lung cancer
The National Institute for Health and Care Excellence (NICE) has published two sets of guidelines boosting the treatment alternatives for National Health Service (NHS) patients with chronic myeloid leukaemia (CML) and non-small cell lung cancer (NSCLC).
- Amgen's Parasabiv, rejected by FDA
As reported in the media, US Food and Drug Administration (FDA) have rejected Amgen's request to market Parsabiv for secondary hyperparathyroidism (sHPT).
- NICE approves non-surgical alternative for fibroids
Women with uterine fibroids stand to benefit from routine access to a non-surgical treatment on the National Health Service (NHS) for the first time, after cost regulators endorsed Gedeon Richter's once-daily pill Esmya as an option.
- Venclexta (venetoclax, AbbVie) joins UK's early access to medicines scheme
As reported in the media, AbbVie venetoclax has been accepted onto the UK's Early Access to Medicines Scheme (EAMS), having receved a positive scientific opinion from the Medicines and Healthcare products Regulatory Agency for the treatment of chronic lymphocytic leukaemia (CLL).
- NICE dismisses Bayer's Nexavar for liver cancer
Nexavar is the latest medicine currently available through the Cancer Drugs Fund (CDF) that has failed to meet cost-effectiveness standards set by the National Institute for Health and Care Excellence (NICE).
- Antibiotics app launched in Scotland
A new app designed to help healthcare staff deal with antibiotic resistance has been launched in Scotland.
- A new digital service that offers online forums and direct access to experts for pregnancy and skin conditions is to be launched
HealthUnlocked, the largest social network dedicated to health in the world, and Doctify, a doctor rating and appointment booking service, are teaming up to provide the new online spaces designed to bring people with similar conditions and needs together.
- Six new medicines gain funding permission for National Health Sevice (NHS) Scotland
Treatment cost regulators for the NHS in Scotland have endorsed routine funding for six drugs, offering patients new treatment options for blood cancer, skin cancer, high cholesterol, diabetes, psoriatic arthritis, and infections in people with cystic fibrosis.
In an unexpected move, just before the end of 2011, ...
Improving expenditure efficiency has been, for a ver...
Your Portal Link to Mass Media Universe.
Valuable Quarterly Romanian Market Analysis.
Ask the analyst
Tailor-made advice for you